Previous 10 | Next 10 |
2023-11-09 07:03:05 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Pharmaceuticals Q3 2023 Earnings Preview Xeris Biopharma tightens FY23 revenue v...
Achieved record revenue of $48.3M – a 27% increase from prior quarter, and a 63% increase from same period prior year Tightens full-year 2023 revenue guidance from $155M-$165M to $160M-$165M Ended Q3 with $66.0M in cash, cash equivalents and short-term investments and remai...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
2023-11-08 12:51:26 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M Seeking Alp...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Xeris Biopharma Holdings Inc. (XERS) is expected to report $-0.12 for Q3 2023
2023-10-16 14:13:43 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Earnings Call Transcript Xeris Pharmaceu...
Raises year-end cash, cash equivalents, and short-term investment guidance from $55M-$65M to $65M-$70M 2023 Cash Utilization expected to be $52M-$57M Tightens 2023 Total Revenue guidance from $145M-$165M to $155M-$165M Received $6M milestone payment for successfully formul...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that on September 26, 2023, it and Xeris Pharmaceuticals, Inc...
2023-09-14 21:41:10 ET Summary Xeris Biopharma Holdings Inc. is making strong progress on the top line and is on track to achieve a positive cash flow breakeven point in 2023. The company holds a substantial number of patents globally, contributing to its success in the pharmaceut...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...